Related references
Note: Only part of the references are listed.Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells
Mengmeng Yang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
Chundi Gao et al.
FRONTIERS IN IMMUNOLOGY (2021)
TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients
Shin Takahashi et al.
BREAST CANCER (2021)
Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins
Chanjuan Zheng et al.
FRONTIERS IN ONCOLOGY (2021)
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
T. Grinda et al.
ESMO OPEN (2021)
Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells
Yan Guo et al.
SCIENCE ADVANCES (2021)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
Joe Yeong et al.
JOURNAL OF CLINICAL PATHOLOGY (2020)
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li et al.
NUCLEIC ACIDS RESEARCH (2020)
Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
Hao Chen et al.
ONCOIMMUNOLOGY (2020)
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
Yanhui Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Optimizing panel-based tumor mutational burden (TMB) measurement
J. Budczies et al.
ANNALS OF ONCOLOGY (2019)
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)
Elizabeth F Blackley et al.
BREAST (2019)
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
Antonio Giordano et al.
PLOS ONE (2019)
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2019)
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta 4/SNAI1/SIRT3 signaling pathway
Shaojia Wang et al.
ONCOGENE (2018)
CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT
Muhammad Zaeem Noman et al.
ONCOIMMUNOLOGY (2018)
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
Zhe-Yu Hu et al.
EBIOMEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival
Ines Vasconcelos et al.
BREAST (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage
Kamila A. Marzec et al.
ONCOTARGET (2015)
Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
Pier Andrea Nicolosi et al.
THERANOSTICS (2015)
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Claudia Geldres et al.
CLINICAL CANCER RESEARCH (2014)
Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy
Jie Li et al.
HUMAN MUTATION (2014)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Stian Knappskog et al.
BREAST CANCER RESEARCH (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells
Craig A. Cooney et al.
BREAST CANCER RESEARCH (2011)
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Xinhui Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
J Andersson et al.
ANNALS OF ONCOLOGY (2005)
Share Paper
